Library

Authors:
V.V. Zakharov ¹ , O.D. Ostroumova ^1.2 , A.I. Kochetkov ² , M.V. Klepikov ² , A.I. Fedin ³

¹ FGAOU VO "First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University);
² FSBEI of DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow;
³ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow

Place of publication:
therapy No. 1 (63) 2023

Summary:
Annotation. Chronic brain ischemia (Khim) is one of the most common in the clinical practice of neurological pathological conditions. The goal is to evaluate the effectiveness and safety of sequential therapy with Mexidol ^® intravenously and Mexidol ^® Fort 250 oral in groups of patients with arterial hypertension (AH) and without the aspect of the drug on cognitive functioning, as well as the severity of asthenic, anxiety, autonomic and motor disorders, and Quality of life in a chemical conditions. Material and methods. Within the framework of subanalysis, patients with chemicals were divided into 4 subgroups: 1st-patients with AH who received drugs Mexidol ^® and Mexidol ^® Forter 250 (n = 144); 2nd-patients with AG who received placebo (n = 146); 3rd-patients without hypertension receiving Mexidol ^® and Mexol ^® Fort 250 (n = 15); 4th-patients without hypertension receiving placebo (n = 12). Results. At the end of the observation period, statistically significant differences in the dynamics of the Mosa scale between groups of patients receiving Mexidol ^® and placebo (p = 0,000), indicating the superior effectiveness of the use of Mexidol in the subgroup of patients with AH, were identified. Against the background of therapy with Mexidol ^® , unlike placebo, the median value of the point on the Mosa scale at the end of the observation period reached the level of norm in all patients. When assessing the secondary endpoints of effectiveness, the statistically significant advantage of Mexidol over the placebo in the population of patients with AH at the final visit was achieved by the following parameters: a test of digital characters, an asthenication scale MFI-20, a Bek anxiety scale, a tinetti scale, and a psychological component of health according to the questionnaire according to the questionnaire SF-36. The comparable nature of the safety profile of Mexidol and placebo is established. Conclusion. The results give reason to recommend the long-term consistent use of the drug Mexidol ^® in the complex treatment of patients with hypertension as an instrument for protecting the brain as an organ-canal and means of pathogenetically substantiated therapy of cognitive, emotional, asthenic, vegetative and motor disorders. Keywords: chronic brain ischemia, arterial hypertension, cognitive disorders, ethylmethydroxypirinate, Mexidol ^® , Mexidol ^® Fort 250.

Authors:

Dhruv Sanjay Gupta, Siddhi Bagwe Parab, Ginpreet Kaur

Translated from Zhurnal Nevrologi I Psikhiatrii Imeni SS Korsakova, Vol. 121, no. 12, ISS. 2, pp. 69–76,
December 2021. Original Article Submitted December 20, 2021. Accepted December 22, 2021.

Place of publication:
Neuroscience and Behavioral Physiology, Vol. 52, no. 5, June, 2022

Summary: Emoxypine and Its Succinate Derivative Share a Common Hydroxypridine Structure, Which Is to Pyridoxine. Thus compounds have been Utilized therapeutically and industrially, Owing to the Wide Range of Properties Offorded. This Includes Antihypoxic, Neuroprotective and Cardioprotective Effects, Along with Pharmacokinetic Benefits Such as the Blood Brain Brain Brain, O Wing to Its Relatively Small Size and Low Molecular Weight. IT Was Observed that Emoxypine Exhibited Iron Chelating Property in Vitro, Indicating Its Usage as a Promising Therapeutic Strategy in the Management of Neurodegenerate ONS SUCH ALZheimer's Disease (Ad), As Well as Hematologic Disorders Like Thalassemia and Hemochromatosis. In Addition to this, it has been Observed to Exert Antioxidant Effect, TheFore, It May BE Considered for the Amelioration of Disoraders Resulting From Free Radical Injury. Studies on Its Mechanism of Action and Implications on Cellular and Molecular Levels Would Help To Further The Understanding of Its Benefits, AS Soles Proospects for For Novel Applications. The Primary Focus of this Review is to dress on the Broad SPACTRUMACOLOGICAL Properties Offered BY Emoxypine and Its Succinate Derivative, and To HIGHHLIGHT THE Cope for An Increased Number of Pre-Clinical and Clinical Trite Assess Its Safety and Efficacy. In Addition to this, The Highlights of this Article Include the Recent Patents Field and Scope for Novel Applications of these Agents.  Keywords: NeuroinflamMation, Mitochondrial Dysfunction, Iron Overload, Mexidol, Acute Kidney Injury, Cerebrooprotection

Authors:
A.I. Fedin ¹ , V.V. Zakharov ² , M.M. Tanashian ³ , E.I. Chukanova ¹ , E.N. Majidova ⁴ , L.A. Shchepankevich ^5.6 , O.D. Ostroumova ⁷

¹ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² FGAOU VO "First Moscow Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University), Moscow, Russia;
³ FGBNU "Scientific Center for Neurology", Moscow, Russia;
⁴ Tashkent Pediatric Medical Institute of the Ministry of Health of the Republic of Uzbekistan, Tashkent, the Republic of Uzbekistan;
⁵ FSBEI in Novosibirsk State Medical University of the Ministry of Health of Russia, Novosibirsk, Russia;
⁶ FGBNU "Federal Research Center for Fundamental and Transalized Medicine", Novosibirsk, Russia;
⁷ FSBEA DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T.121, No. 11

Summary:
Purpose of the study. To evaluate the effectiveness and safety of consistent therapy with the drug Mexidol intravenously and Mexidol Forte 250 orally in patients with chronic brain ischemia.

Material and methods. In the international multicenteric randomized double-blind-controlled study, 318 patients with a chemical place from 40 to 90 years are included in 15 clinical centers, located in the territory of the Russian Federation and the Republic of Uzbekistan. Patients were randomized in 2 groups, patients of the 1st group received Mexidol intravenously 500 mg once a day for 14 days, then Mexidol Forte 250 was prescribed orally 250 mg 3 times a day for the next 60 days; Patients of the 2nd group received placebo in a similar mode. As the primary criterion for effectiveness, the average value of the change in the point on the MOCA scale was chosen at the stage of completion of the study by the patient compared to the initial level.

Results. Upon completion of the study between the 1st and 2nd groups, reliable differences were identified by the result of the MOCA scale (p <0.000001). The lower boundary of 95% of the trust interval for the difference in the average indicators of the main criterion for the effectiveness between the 1st and 2nd groups was 1.51, which allows the higher efficiency of the use of Mexidol. According to the secondary endpoints, a statistically significant advantage over the placebo at the final visit was achieved by the following parameters: a test of digital symbol replacements, an asthenia assessment scale, a Bek anxiety scale, a tineta questionnaire, a Tinetti scale, a SF-36 questionnaire (psychological component of health), and a psychological component of health). CGI scale (a general clinical impression scale). The comparable nature of the safety profile of Mexidol and placebo is established.

Conclusion. The validity and expediency of the consistent use of Mexidol and Mexidol Forte 250 in the treatment of patients with chemicals are demonstrated.

Keywords: chronic brain ischemia, cognitive disorders, neuropsychological testing, ethylmethylhydroxypyrididine succinate, Mexidol, Mexidol Forte 250, treatment of chemicals, examination of memes.

Place of publication:
Medical alphabet No. 19/2017, volume No. 3. Emergency medicine

Summary:
relevance. Neuroprotection is a mandatory component of intensive care of cerebral disasters in the prehospital and hospital stages of medical care. Target. Identification of the characteristics and adequacy of the ambulance personnel of the methods of neuroprotheres in various cerebral disasters. Materials and methods. To determine the level of knowledge and practical skills of neuroprotection of various cerebral disasters, anonymous voluntary questioning of 109 doctors of the SMP stations and 103 paramedics of the Voronezh city ambulance station was carried out. The effectiveness of the use of neuroprotectors for cerebral disasters was studied using a special protocol attached to the Chargage map of the Voronezh ambulance station. Results. Theoretical training in the neuroprotection section is considered sufficient 75 % of doctors and 57 % of paramedics. 25 % of doctors and 35 % of paramedics are considered insufficient theoretical training. The use of Mexidol intensive therapy in the intensive care of the prehospital stage has a pronounced positive clinical effect.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T. 121, No. 10, Issue. 2

Summary:
in a review article, modern approaches to testing and registration of reproduced (generic) drugs are considered. The history of the formation of a methodology for research of reproduced drugs and modern legislation of the Russian Federation is presented. The stages of confirmation of the equivalence of original and reproduced drugs are described: pharmaceutical equivalence, bioequivalence and therapeutic equivalence. Methods of evaluating bioequivalence as a basic study in the registration of reproduced drugs are analyzed in detail. On the example of the original domestic neuroprotector of the drug Mexidol (ethylmethylhydroxypyrididine of succinate) and its generiks described how legislative acts are implemented in practice. It is concluded that not all reproduced drugs can be interchangeable with the original drug.

Keywords: original and reproduced drugs, generics, ethylmethylhydroxypyridine succinate, Mexidol.

Place of publication:
neurology, neuropsychiatry, psychosomatics. 2021; 13 (6)

Summary:
The review discusses the interchangeability of drugs (drugs), approaches to registering original and reproduced drugs and types of equivalence, as well as problems with generics in clinical practice. The results of pharmacoepidemiological studies, widely leading in recent years, indicate an insufficient study of the influence of reproduced drugs on remote outcomes of chronic diseases, including mortality. The long-term economic prospect of the use of reproduced drugs remains unclear. The main reasons for the difference between the original and reproduced drugs include differences in the methods of synthesis of active substances, as well as as part of auxiliary substances and impurities. Comparative studies of the therapeutic equivalence of generics with the original and are carried out quite rarely and often suffer from methodological disadvantages, which does not guarantee comparable efficiency and safety of such drugs. In this regard, the automatic replacement of drugs containing the same active substance, without the participation of the attending physician, should be avoided.

Keywords: generics; bioequivalence; pharmaceutical equivalence; therapeutic equivalence; interchangeability.

Authors:
L.V. Stakhovskaya ¹ , E.A. Mkhitaryan ² , O.N. Tkachev ^1.2 , T.M. Ostroumova ³ , O.D. Ostroumova ^3.4

¹ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² Russian Gerontological Scientific and Clinical Center of the FGAOU in the Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
³ FGAOU in the First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University), Moscow, Russia;
⁴ FSBEI of DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T.120, No. 8, Issue 2

Summary:
Purpose of the study. To evaluate the effectiveness and safety of prolonged sequential therapy with Mexidol with a hemisphere ischemic stroke in acute and early recovery periods in patients of various age groups.

Material and methods. The study is an additional analysis of age groups among 150 patients who took part in a randomized double blind multicenter placebo-controlled in parallel groups of the epic study. The entire study of the study (62 men and 88 women) was divided into subgroups by age: under 60 years old, 60–75 years old, 76–90 years. Also, all participants in the study were divided into 2 populations: ITT (Intent to Treat Population, patients who received at least one dose of the drug/placebo drug) and PP (Per Protocol Population, patients who received the drug in accordance with the research protocol). The results were evaluated on the modified Rankin scale (MSHR) at the end of the course of therapy, the Bartel index, the Bek depression scale, and the European questionnaire for assessing the quality of life.

Results. The effectiveness of Mexidol on all the scales used did not differ depending on age. At the time of the end of the therapy, the average MSHR score was lower in patients 76–90 years (in both populations) compared to placebo (p <0.001). The dynamics of reducing the average score in MSHR (1-5th visits) was more pronounced in patients of 60–75 years (p = 0.025), including patients with diabetes. In patients 76–90 years old and patients with diabetes mellitus compared to placebo, the severity of cognitive-affective symptoms of depression (p = 0.049 and p = 0.02, respectively), the share of patients with lack of problems with everyday affairs, increased statistically significant (P = P = P = P = P = P = P = P = P = P = P. 0.007 and p = 0.02, respectively). In patients with diabetes, the level of everyday activity (p = 0.023) has also increased statistically significantly significantly increased and the quality of life has improved (p = 0.045). There were no reliable differences in the frequency of unwanted phenomena in all studied groups.

Conclusion. It is recommended that the use of Mexidol in the acute and early recovery periods of ischemic stroke in all age groups, including patients with diabetes mellitus.

Key words: ischemic stroke, Mexidol, ethylmethylhydroxypyridine succinate, effectiveness and safety, ischemic stroke, acute period, early recovery period, epic.

Presidium of the Council of Experts:

Martynov A.I., MD, professor, academician of the Russian Academy of Sciences, professor of the Department of Hospital therapy No. 1 of the Federal State Budgetary Institution “Moscow State Medical and Dental University named after A.I. Evdokimova "of the Ministry of Health of Russia, President of the Russian Scientific Medical Society of therapists (RNDMO), Moscow

Tanashian M.M., MD, professor, corresponding member of the Russian Academy of Sciences, deputy. Director for scientific work of the FGBN “Scientific Center of Neurology”, Moscow

Malyavin A.G., MD, professor at the Department of Testions and Pulmonology Faculty of Faculty of Faculty of FSBEI in the Moscow State Medical and Dental University named after A.I. Evdokimova ”of the Ministry of Health of Russia, chief freelance pulmonologist of the Ministry of Health of Russia for the Central Federal District, General Secretary of the RND, Moscow

Participants in the Council of Experts:

Bogolepova A.N. D.M.N., head of the cognitive violations department of the Federal Center for Brain and Neurotechnology, FMBA of Russia, professor of the Department of Neurology, Neurosurgery and Medical Genetics of Faculty of Faculty of Faculty of Medicine in the Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of Russia, Moscow

Borovkova N.Yu., MD, the first deputy. Director of the Institute of Therapy, Professor of the Department of Hospital Therapy and General Medical Practice of the Volga Research Medical University of the Ministry of Health of Russia, Nizhny Novgorod.

Eliseeva L.N., MD, professor, head. Department of Faculty of Faculty of FSBENSI and Kuban State Medical University of the Ministry of Health of Russia, Chairman of the Krasnodar Regional Branch of the RND, Krasnodar

Zhuravleva M.V., MD, professor, professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases of the FGAOU in the First Moscow State Medical University named after THEM. Sechenova "of the Ministry of Health of Russia (Sechenov University), the main freelance specialist - a clinical pharmacologist of the Department of Health of the city of Moscow, Moscow

Zakharov V.V., MD, professor at the Department of Nervous Diseases and Neurosurgery of the FGAOU in "First Moscow State Medical University named after THEM. Sechenova "of the Ministry of Health of Russia (Sechenov University), Moscow

Koryagina N.A., MD, professor at the Department of Clinical therapy of FSBEI in Perm State Medical University named after Academician E.A. Wagner ”of the Ministry of Health of Russia, Vice-President of the Association of Doctors of the therapeutic Profile of the Perm Territory, Chairman of the Perm Regional Department of the RND, Chief Forest Transportist of the Ministry of Health of the Perm Territory, Perm Perm

Mikhin V.P., MD, professor, head. Department of Internal Diseases No. 2 of the FSBEI in “Kursk State Medical University” of the Ministry of Health of Russia, Kursk

Osipova I.V., MD, professor, head. Department of Faculty Therapy and Professional Diseases of the FSBEI in Altai State Medical University of the Ministry of Health of Russia, Barnaul

Ostroumova O.D., MD, professor, head. Department of Therapy and Polymorbid Pathology of the Federal State Budgetary Institution of the DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow

Poznyak A.O., MD, professor, head. The Department of Therapy, Geriatrics and the General Practice of the Kazan State Medical Academy - a branch of the Federal State Budgetary Institution of the DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Kazan Kazan

Portnyagina U.S., Ph.D., Associate Professor of the Department of Internal Diseases and General Personnel Practice (Family Medicine) of the FGOU FGAOU in North-East Federal University named after M.K. Ammosova ”, the main freelance specialist in therapy and general medical practice of the Ministry of Health of the Republic of Sakha (Yakutia), Yakutsk

Statsenko M.E., MD, professor, head. Department of Internal Diseases of the FSBEI in Volgograd State Medical University of the Ministry of Health of Russia, Volgograd

Tyrenko V.V., MD, professor, head of the department and clinic of the faculty therapy of the Federal State Budgetary Institution “Military Medical Academy named after S.M. Kirov »of the Ministry of Defense of the Russian Federation, chief cardiologist of the Ministry of Defense of the Russian Federation, St. Petersburg St.

Chesnikova A.I., MD, professor, head. Department of Internal Diseases No. 1 of the Federal State Budgetary Institution “Rostov State Medical University” of the Ministry of Health of Russia, the main freelance specialist in therapy of the Southern Federal District, Rostov-on-Don

Place of publication:
therapy No. 10 (72) 2023

Resume by resolution:

• The brain of AH is one of the target organs , the first symptoms of the lesion of which are vascular cognitive impairment (SKN).
• It is necessary to carry out neuropsychological testing to identify and assess the severity of SKN. The management and examination of patients with AG is carried out by the primary outpatient doctor.
• For effective treatment of SKN, antihypertensional therapy is not enough, a neuroprotection program is needed.
• The choice of a neuroprotector should be based on the evidence base and good tolerance of the drug. In order to reduce polypragmasis, it is necessary to focus on drugs with a multimodal action mechanism ( Mexidol ^® ).
• The recommended scheme of sequential therapy with Mexidol, according to the results of clinical studies, including randomized, 200-500 mg/day intravenously or intramuscularly for 14 days with a transition to a periral form, 250 mg 3 times/day for 60 days.
• Neuroprotection should serve as an integral part of patients with AG. It is recommended to supplement the algorithm for drug treatment of patients with hypertension by turning on ethylmethylhydroxypyridine of succinate (Mexidol ^® ) in the clinical recommendations “Arterial hypertension in adults” (i10/i11/i12/i13/i15, according to ICD-10).

Place of publication:
New therapeutic journal Non Nocera, September, 2023

Summary:
arterial hypertension (AH) is currently a very urgent problem of modern society. Its prevalence among an adult population is an average of 30–45%, significantly increasing in older age groups. In addition, due to the expected increase in life expectancy, an increase in the number of patients with AH is predicted. From the point of view of clinical significance, special attention to AH is due to a wide range of complications caused by the disease and involved target organs, including the heart, blood vessels, kidneys, organ of vision and brain. Several large population studies showed that the higher the office blood pressure (blood pressure), the higher the risk of stroke, coronary heart disease, heart failure, peripheral arterial diseases, and the terminal stage of renal failure and sudden death. AH is also recognized as one of the pathogenetic factors of the development of vascular cognitive impairment (KN) and Alzheimer's disease. However, before achieving the final stage - dementia, patients are sequentially intermediate stages between the normal level of cognitive functioning and the very difficult KN, as the cognitive status develops progressively, gradually violating the quality of life and negatively affecting the adaptation of a person in various fields of daily activities. There are many studies that clearly established the relationship between increased blood pressure and KN and demonstrated that the latter are one of the earliest manifestations of brain damage against the background of hypertension.

Place of publication:
therapy No. 9 (61) 2022

Summary:
Cognitive disorders (KN) - a widespread clinical syndrome, with which specialists of various profiles are often found in outpatient reception. Diagnosis of KN is a responsible task, the correct solution of which requires a comprehensive study of the anamnesis, the nature of the clinical picture, the results of a laboratory and instrumental examination. A common cause of KN is cerebrovascular diseases. The article discusses the issues of patients with KN of vascular genesis, in particular, the main aspects of correction of factors of cardiovascular risk, the choice of optimal drug therapy. Information is given about the possibility of using the drug Mexidol to treat this contingent of patients. The results of studies are analyzed by the study of the possibility of the use of Mexidol in chronic cerebrovascular circulation disorders with KN. Key words: chronic brain ischemia, chronic cerebrovascular diseases, a disease of small cerebral arteries, cognitive impairment, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T. 122, No. 5

Summary:
Purpose of the study. To study the leading pathogenetic mechanisms that underlie the development of complications of diabetes (diabetes) of the 2nd type and optimize therapeutic approaches to the treatment of this category of patients. Material and methods. The results of treatment are presented 30 patients suffering from type 2 diabetes and its complications who received Mexidol in/in a drop of 500 mg/day for 14 days, with the subsequent transition to the oral reception of Mexol Fort 250 to 250 mg 3 times a day in the course of 60 days. The dynamics of the condition was evaluated by standardized neuropsychological scales. Clinical and biochemical studies are performed according to the protocol of patients with type 2 diabetes. Results. Mexidol therapy according to the presented scheme was accompanied by an improvement in cognitive functions, a decrease in signs of asthenia, anxiety and depression, normalization of sleep, improving biochemical blood indicators, and an increase in the quality of life. Conclusion. The appointment of Mexidol in the form of consistent prolonged therapy may be an effective approach, which allows you to improve the quality of life of patients with type 2 diabetes. Keywords: diabetes, hypoxia, oxidative stress, antioxidants, neurotransmitters, antihypoxants, Mexidol.

Place of publication:
New therapeutic journal Non Nocera, August 2021

Summary:
For centuries, every representative of the fair sex wanted to stay young and beautiful as long as possible. For this, for example, Queen Cleopatra or Queen of England Elizabeth I daily took baths with milk (cows, goats, donkeys, etc.). In the Victorian era, women for the sake of whiteness of skin applied creams containing lead, which definitely did not contribute to health and a long happy life, the duration of which began to increase only in the twentieth century against the backdrop of the rapid development of medical science. According to the World Health Organization, for the period from 2015 to 2050, the number of people 60+ will increase from 900 million to 2 billion (from 12 to 22% in the total population of the world), that is, each 5th person will be over 60 years old. But is it possible to slow down even more or completely stop the aging process, and what is needed for this?

Place of publication:
New therapeutic journal Non Nocera, December, 2020

Resume:
asthenia (Greek “powerlessness”, “lack of strength”)-a protective-compensator reaction of the body to any state that threatens the exhaustion of energy resources, and by definition in ICD-10-“a constant sensation and/or complaints about a sense of general weakness, increased fatigue (with any type of load), as well as a decrease in working capacity in combination with 2 or more of the following complaints: muscle pain; headaches of tension; dizziness; sleep disturbances; dyspepsia; inability to relax; irritability".

Clinical manifestations of asthenic syndrome (AS) can be divided into:

• physical (muscle weakness, fatigue, exhaustion);

• emotional-psychological (emotional lability, irritability, a sense of internal tension, lowered mood background, apathetic);

• cognitive (decrease in mental performance, memory, concentration of attention);

• Sleep disorders (insomnia, drowsiness).

Place of publication:
New therapeutic magazine "Non Nocera", November, 2020

Summary:
arterial hypertension (AH) is an important medical and social problem around the world. The disease is often called the "silent killer" (English Silent Killer, since most patients are quite difficult to suspect the earliest symptoms of the lesions of target organs mediated by AH. Moreover, in patients with systolic blood pressure (garden)> 130 mm RT. Art. In the middle age, the risk of dementia in old age increases by 34%. According to the current clinical recommendations, the manifestations of the brain damage to AH are considered to be the so-called dumb (asymptomatic) lacunar heart attacks, hyperinathery changes in the white substance of the brain and cerebral micro-power, which are detected by magnetic resonance tomography (MRI). The clinical manifestation of brain damage as a target organ is cognitive impairment (KN). The recommendations for the treatment of patients from AH 2018 emphasize that MRI is an enough examination method, which does not allow it to use it for routine screening. However, neuroizualization, that is, an MRI, is necessary for patients with clinical signs of cognitive disorders (KF). Consequently, a competent and timely detection of cognitive complaints, signs of KN and their correction in patients with AH is an extremely important task for a doctor of any specialty.

Place of publication:
therapy No. 6 (40) 2020

Summary:
the purpose of the study is to evaluate the effectiveness, safety and the possibility of correcting the neuropsychiatric manifestations of chronic brain ischemia (chemical) drugs Mexidol ^® and Mexidol ^® Forte 250 within the framework of consecutive therapy against the background of arterial hypertension, atherosclerosis (IBS), osteoarthritis or OA) or OA) or OA) rheumatoid arthritis (RA). Material and methods. 134 patients 45–75 years old with a neuroimulated chemical chemicized, combined with hypertension, coronary heart disease and articular pathology were examined. Group 1 (observations) included 79 patients - 30 patients with RA (subgroup 1A) and 49 with the ot of the knee joints (subgroup 1b), who received in the complex therapy Mexidol ^® and Mexidol ^® Fort 250. Group 2 (control) amounted to 55 patients - 25 patients with RA (subgroup 2A) and 30 - with OA (subgroup 2B), which used to use basic therapy without the addition of Mexidol. The dynamics of subjective and physical symptoms were evaluated, values ​​on the scales of CGI, Mosa, MFI 20, anxiety and depression of Hamilton, Tinnetti. Mexidol ^® was prescribed intravenously (500 mg per day) for 14 days with the subsequent oral administration of the drug Mexidol ^® Fort 250 at 250 mg 3 times/day another 60 days. Results. ^® and Mexidol ^® to the standard treatment of drugs in the framework of consistent therapy contributed to an increasing improvement in all studied indicators. In the control groups, the cognitive status did not change. The use of initiating intravenous therapy with Mexidol increased the adherence of patients to the prolonged use of the drug. Conclusion. Violations of the locomotor function in polymorbid patients are partially associated with chemicals. The additional purpose of the consistent infusion and tablet forms of Mexidol significantly improves cognitive functions with the correction of the stability of walking, asthenic manifestations, and increases the motivation for active life. Key words: chronic brain ischemia, Mexidol ^® , Mexidol ^® Fort 250, osteoarthritis, rheumatoid arthritis, arterial hypertension, coronary heart disease.

Place of publication:
New therapeutic journal "Non Nocera" No. 4, 2019

Summary:
acute respiratory diseases or, as it is customary to name them, acute respiratory infections (Ori) is an urgent problem of modern medicine, especially during periods of sharp fluctuations in the temperature and humidity of the environment, when the traditionally expected incidence of influenza and other visual or mixtures increases sharply .